$-0.28 EPS Expected for Spectrum Pharmaceuticals, Inc. (SPPI)

April 20, 2018 - By Linda Rogers

Investors sentiment decreased to 1.63 in 2017 Q4. Its down 1.21, from 2.84 in 2017Q3. It turned negative, as 26 investors sold Spectrum Pharmaceuticals, Inc. shares while 28 reduced holdings. 27 funds opened positions while 61 raised stakes. 78.22 million shares or 9.25% more from 71.60 million shares in 2017Q3 were reported.
Principal Financial Grp Inc reported 702,317 shares. Leucadia National holds 0.03% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) or 18,934 shares. Citigroup owns 166,092 shares. Schwab Charles accumulated 458,450 shares or 0.01% of the stock. Barclays Pcl stated it has 1.09M shares or 0.02% of all its holdings. Envestnet Asset Mgmt has invested 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Legal & General Grp Public Limited Com reported 163,810 shares stake. Morgan Stanley holds 242,128 shares or 0% of its portfolio. Grantham Mayo Van Otterloo Co reported 21,600 shares. Pub Employees Retirement Association Of Colorado has 31,800 shares. Nordea reported 92,400 shares. Blackrock has 0.01% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 15.99 million shares. Fmr Ltd Co holds 7.04M shares or 0.02% of its portfolio. Parametric Portfolio Associate Limited Liability Com holds 0% or 151,592 shares. Fisher Asset Mngmt Limited Liability Company reported 200,252 shares.

Since March 21, 2018, it had 0 insider purchases, and 13 insider sales for $6.83 million activity. 90,000 shares were sold by SHROTRIYA RAJESH C MD, worth $1.83M. Shares for $30,350 were sold by Riga Thomas J. 3,100 shares were sold by Turgeon Joseph W., worth $56,327 on Thursday, March 22. On Wednesday, March 21 the insider Krassner Stuart Mitchell sold $78,278.

Analysts expect Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) to report $-0.28 EPS on May, 1.They anticipate $0.10 EPS change or 55.56 % from last quarter’s $-0.18 EPS. After having $-0.29 EPS previously, Spectrum Pharmaceuticals, Inc.’s analysts see -3.45 % EPS growth. The stock decreased 1.43% or $0.27 during the last trading session, reaching $18.59. About 270,110 shares traded. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has risen 143.80% since April 20, 2017 and is uptrending. It has outperformed by 132.25% the S&P500.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Ratings Coverage

Among 3 analysts covering Spectrum Pharmaceuticals (NASDAQ:SPPI), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Spectrum Pharmaceuticals had 4 analyst reports since October 24, 2017 according to SRatingsIntel. The stock has “Buy” rating by FBR Capital on Tuesday, April 10.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company has market cap of $1.89 billion. The firm markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It currently has negative earnings. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: